The impact of PECS II blockade in patients undergoing minimally invasive cardiac surgery—a prospective, randomized, controlled, and triple-blinded trial
Abstract Background Classic neuraxial techniques, such as thoracic epidural anesthesia, or alternative approaches like the paravertebral block, are not indicated in cardiac surgery due to increased bleeding risk. To provide satisfactory analgesia without the need for excessive opioid use, novel ultr...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-09-01
|
Series: | Trials |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13063-023-07530-7 |
_version_ | 1797451655682195456 |
---|---|
author | Elisabeth Hoerner Ottokar Stundner Felix Naegele Anna Fiala Nikolaos Bonaros Peter Mair Johannes Holfeld Lukas Gasteiger |
author_facet | Elisabeth Hoerner Ottokar Stundner Felix Naegele Anna Fiala Nikolaos Bonaros Peter Mair Johannes Holfeld Lukas Gasteiger |
author_sort | Elisabeth Hoerner |
collection | DOAJ |
description | Abstract Background Classic neuraxial techniques, such as thoracic epidural anesthesia, or alternative approaches like the paravertebral block, are not indicated in cardiac surgery due to increased bleeding risk. To provide satisfactory analgesia without the need for excessive opioid use, novel ultrasound techniques gained popularity and are of growing interest. The pectoralis nerve block II (PECS II) has been shown to provide good postoperative analgesia in modified radical mastectomy and might also be suitable for minimally invasive cardiac surgery. Methods In a single center, prospective, triple-blinded, two-group randomized trial, 60 patients undergoing elective, unilateral minimal invasive cardiac surgery will be randomized to receive a PECS II with 30 ml of ropivacaine 0.5% (intervention group) or sodium chloride 0.9% (placebo group). The primary outcome parameter is the overall opioid demand given as intravenous morphine milligram equivalents (MME) during the first 24 h after extubation. Secondary endpoints are the visual analog scale (VAS) 2, 4, 6, 8, 12, and 24 h after extubation, the Overall Benefit of Analgesia Score (OBAS) after 24 h, the interval until extubation, and intensive care unit (ICU) discharge within 24 h, as well as the length of hospital stay (LOS). Discussion This prospective randomized, controlled, and triple-blinded trial aims to assess if a PECS II with ropivacaine 0.5% helps to decrease the opioid demand in the first 24 h and increases postoperative pain control after minimally invasive cardiac surgery. Trial registration www.clinicaltrialsregister.eu ; EudraCT Nr: 2021–005452-11; Lukas Gasteiger MD, November 18, 2021. |
first_indexed | 2024-03-09T14:56:39Z |
format | Article |
id | doaj.art-ee4552a2071244b9bf339ad454ad62d1 |
institution | Directory Open Access Journal |
issn | 1745-6215 |
language | English |
last_indexed | 2024-03-09T14:56:39Z |
publishDate | 2023-09-01 |
publisher | BMC |
record_format | Article |
series | Trials |
spelling | doaj.art-ee4552a2071244b9bf339ad454ad62d12023-11-26T14:09:31ZengBMCTrials1745-62152023-09-0124111010.1186/s13063-023-07530-7The impact of PECS II blockade in patients undergoing minimally invasive cardiac surgery—a prospective, randomized, controlled, and triple-blinded trialElisabeth Hoerner0Ottokar Stundner1Felix Naegele2Anna Fiala3Nikolaos Bonaros4Peter Mair5Johannes Holfeld6Lukas Gasteiger7Department of Anaesthesiology and Intensive Care Medicine, Medical University of InnsbruckDepartment of Anaesthesiology and Intensive Care Medicine, Medical University of InnsbruckDepartment of Cardiac Surgery, Medical University of InnsbruckDepartment of Anaesthesiology and Intensive Care Medicine, Medical University of InnsbruckDepartment of Cardiac Surgery, Medical University of InnsbruckDepartment of Anaesthesiology and Intensive Care Medicine, Medical University of InnsbruckDepartment of Cardiac Surgery, Medical University of InnsbruckDepartment of Anaesthesiology and Intensive Care Medicine, Medical University of InnsbruckAbstract Background Classic neuraxial techniques, such as thoracic epidural anesthesia, or alternative approaches like the paravertebral block, are not indicated in cardiac surgery due to increased bleeding risk. To provide satisfactory analgesia without the need for excessive opioid use, novel ultrasound techniques gained popularity and are of growing interest. The pectoralis nerve block II (PECS II) has been shown to provide good postoperative analgesia in modified radical mastectomy and might also be suitable for minimally invasive cardiac surgery. Methods In a single center, prospective, triple-blinded, two-group randomized trial, 60 patients undergoing elective, unilateral minimal invasive cardiac surgery will be randomized to receive a PECS II with 30 ml of ropivacaine 0.5% (intervention group) or sodium chloride 0.9% (placebo group). The primary outcome parameter is the overall opioid demand given as intravenous morphine milligram equivalents (MME) during the first 24 h after extubation. Secondary endpoints are the visual analog scale (VAS) 2, 4, 6, 8, 12, and 24 h after extubation, the Overall Benefit of Analgesia Score (OBAS) after 24 h, the interval until extubation, and intensive care unit (ICU) discharge within 24 h, as well as the length of hospital stay (LOS). Discussion This prospective randomized, controlled, and triple-blinded trial aims to assess if a PECS II with ropivacaine 0.5% helps to decrease the opioid demand in the first 24 h and increases postoperative pain control after minimally invasive cardiac surgery. Trial registration www.clinicaltrialsregister.eu ; EudraCT Nr: 2021–005452-11; Lukas Gasteiger MD, November 18, 2021.https://doi.org/10.1186/s13063-023-07530-7PECS II blockFascial plane blockMinimal invasive cardiac surgeryClinical trial |
spellingShingle | Elisabeth Hoerner Ottokar Stundner Felix Naegele Anna Fiala Nikolaos Bonaros Peter Mair Johannes Holfeld Lukas Gasteiger The impact of PECS II blockade in patients undergoing minimally invasive cardiac surgery—a prospective, randomized, controlled, and triple-blinded trial Trials PECS II block Fascial plane block Minimal invasive cardiac surgery Clinical trial |
title | The impact of PECS II blockade in patients undergoing minimally invasive cardiac surgery—a prospective, randomized, controlled, and triple-blinded trial |
title_full | The impact of PECS II blockade in patients undergoing minimally invasive cardiac surgery—a prospective, randomized, controlled, and triple-blinded trial |
title_fullStr | The impact of PECS II blockade in patients undergoing minimally invasive cardiac surgery—a prospective, randomized, controlled, and triple-blinded trial |
title_full_unstemmed | The impact of PECS II blockade in patients undergoing minimally invasive cardiac surgery—a prospective, randomized, controlled, and triple-blinded trial |
title_short | The impact of PECS II blockade in patients undergoing minimally invasive cardiac surgery—a prospective, randomized, controlled, and triple-blinded trial |
title_sort | impact of pecs ii blockade in patients undergoing minimally invasive cardiac surgery a prospective randomized controlled and triple blinded trial |
topic | PECS II block Fascial plane block Minimal invasive cardiac surgery Clinical trial |
url | https://doi.org/10.1186/s13063-023-07530-7 |
work_keys_str_mv | AT elisabethhoerner theimpactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT ottokarstundner theimpactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT felixnaegele theimpactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT annafiala theimpactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT nikolaosbonaros theimpactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT petermair theimpactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT johannesholfeld theimpactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT lukasgasteiger theimpactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT elisabethhoerner impactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT ottokarstundner impactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT felixnaegele impactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT annafiala impactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT nikolaosbonaros impactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT petermair impactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT johannesholfeld impactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial AT lukasgasteiger impactofpecsiiblockadeinpatientsundergoingminimallyinvasivecardiacsurgeryaprospectiverandomizedcontrolledandtripleblindedtrial |